RESUMO
A novel tertiary amine series of potent muscarinic M(3) receptor antagonists are described that exhibit potential as inhaled long-acting bronchodilators for the treatment of chronic obstructive pulmonary disease. Geminal dimethyl functionality present in this series of compounds confers very long dissociative half-life (slow off-rate) from the M(3) receptor that mediates very long-lasting smooth muscle relaxation in guinea pig tracheal strips. Optimization of pharmacokinetic properties was achieved by combining rapid oxidative clearance with targeted introduction of a phenolic moiety to secure rapid glucuronidation. Together, these attributes minimize systemic exposure following inhalation, mitigate potential drug-drug interactions, and reduce systemically mediated adverse events. Compound 47 (PF-3635659) is identified as a Phase II clinical candidate from this series with in vivo duration of action studies confirming its potential for once-daily use in humans.
Assuntos
Azetidinas/síntese química , Broncodilatadores/síntese química , Ácidos Difenilacéticos/síntese química , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Receptor Muscarínico M3/antagonistas & inibidores , Administração por Inalação , Animais , Azetidinas/química , Azetidinas/farmacologia , Broncodilatadores/química , Broncodilatadores/farmacologia , Células CHO , Linhagem Celular , Permeabilidade da Membrana Celular , Cricetinae , Cricetulus , Ácidos Difenilacéticos/química , Ácidos Difenilacéticos/farmacologia , Cães , Feminino , Cobaias , Hepatócitos/metabolismo , Humanos , Técnicas In Vitro , Cinética , Masculino , Microssomos Hepáticos/metabolismo , Relaxamento Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Músculo Liso/fisiologia , Ensaio Radioligante , Ratos , Receptor Muscarínico M3/metabolismo , Proteínas Recombinantes/antagonistas & inibidores , Proteínas Recombinantes/metabolismo , Estereoisomerismo , Relação Estrutura-Atividade , Traqueia/efeitos dos fármacos , Traqueia/fisiologiaRESUMO
Heteroarylalanine derivatives 4 were designed as potential inhibitors of neutral endopeptidase (NEP EC 3.4.24.11). Selectivity over other zinc metalloproteinases was explored through occupation of the S2' subsite within NEP. Structural optimisation led to the identification of 5-phenyl oxazole 4f, a potent and selective NEP inhibitor. A crystal structure of the inhibitor bound complex is reported.